CONTROVERSIES IN THE MANAGEMENT OF NON-SMALL CELL LUNG-CANCER - THE RESULTS OF AN EXPERT SURROGATE STUDY

被引:43
作者
PALMER, MJ
OSULLIVAN, B
STEELE, R
MACKILLOP, WJ
机构
[1] UNIV EDINBURGH, DEPT CLIN ONCOL, EDINBURGH EH8 9YL, MIDLOTHIAN, SCOTLAND
[2] ONTARIO CANC INST, TORONTO M4X 1K9, ONTARIO, CANADA
[3] QUEENS UNIV, DEPT COMMUNITY HLTH & EPIDEMIOL, KINGSTON K7L 3N6, ONTARIO, CANADA
[4] KINGSTON REG CANC CTR, KINGSTON, ONTARIO, CANADA
关键词
Clinical trials; Decision-making; Medical ethics; Non-small cell lung cancer;
D O I
10.1016/0167-8140(90)90162-P
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Four hundred and sixty-one doctors who treat lung cancer in Canada and the United States answered a questionnaire in which they were asked how they would wish to be managed if they developed non-small cell lung cancer (NSCLC). There was no evidence of a consensus as to preferred treatment in either of two clinical situations described. Personal treatment preferences were significantly influenced by specialist training and each discipline showed a preference for its own modality of treatment. The personal treatment preferences of American and Canadian doctors differed significantly. In the United States, the role of surgery in NSCLC with extensive mediastinal disease was controversial, whereas in Canada, the major controversy was whether any active treatment was desirable in this situation if symptoms were absent. The role of chemotherapy in the treatment of NSCLC with painful bone metastases was controversial in the United States, but the vast majority of Canadian doctors would not wish any form of chemotherapy in this situation. Respondents were also asked what treatment they usually recommended for patients with NSCLC in the two situations described. Almost all these doctors recommended for their patients exactly the same treatment which they would choose for themselves. It was concluded that the personal treatment preferences of doctors are an important factor in determining how patients with NSCLC are treated. Doctors were also asked (a) if they would be willing to participate as patient-subjects in a number of clinical trials for which they would be eligible if they developed NSCLC, and (b) if they would be willing to ask their patients to participate in the same trials. There were significant differences in the perceived acceptability of the trials studied, but in each case a higher proportion of doctors would be willing to ask their patients to participate than would be prepared to consent themselves. © 1990.
引用
收藏
页码:17 / 28
页数:12
相关论文
共 10 条
[1]  
CORMIER Y, 1982, CANCER, V50, P845, DOI 10.1002/1097-0142(19820901)50:5<845::AID-CNCR2820500507>3.0.CO
[2]  
2-S
[3]   EQUIPOISE AND THE ETHICS OF CLINICAL RESEARCH [J].
FREEDMAN, B .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (03) :141-145
[4]   SOCIAL AND ECONOMIC-FACTORS IN THE CHOICE OF LUNG-CANCER TREATMENT - A POPULATION-BASED STUDY IN 2 RURAL STATES [J].
GREENBERG, ER ;
CHUTE, CG ;
STUKEL, T ;
BARON, JA ;
FREEMAN, DH ;
YATES, J ;
KORSON, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (10) :612-617
[5]  
MACKILLOP WJ, 1988, HUM MED, V4, P89
[6]   CLINICAL-TRIALS IN CANCER - THE ROLE OF SURROGATE PATIENTS IN DEFINING WHAT CONSTITUTES AN ETHICALLY ACCEPTABLE CLINICAL EXPERIMENT [J].
MACKILLOP, WJ ;
PALMER, MJ ;
OSULLIVAN, B ;
WARD, GK ;
STEELE, R ;
DOTSIKAS, G .
BRITISH JOURNAL OF CANCER, 1989, 59 (03) :388-395
[7]   NON-SMALL CELL LUNG-CANCER - HOW ONCOLOGISTS WANT TO BE TREATED [J].
MACKILLOP, WJ ;
OSULLIVAN, B ;
WARD, GK .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1987, 13 (06) :929-934
[8]   THE USE OF EXPERT SURROGATES TO EVALUATE CLINICAL-TRIALS IN NON-SMALL CELL LUNG-CANCER [J].
MACKILLOP, WJ ;
WARD, GK ;
OSULLIVAN, B .
BRITISH JOURNAL OF CANCER, 1986, 54 (04) :661-667
[9]   HOW IS CANCER-TREATMENT CHOSEN [J].
MAYER, RJ ;
PATTERSON, WB .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (10) :636-638
[10]   CHEMOTHERAPY CAN PROLONG SURVIVAL IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER - REPORT OF A CANADIAN MULTICENTER RANDOMIZED TRIAL [J].
RAPP, E ;
PATER, JL ;
WILLAN, A ;
CORMIER, Y ;
MURRAY, N ;
EVANS, WK ;
HODSON, DI ;
CLARK, DA ;
FELD, R ;
ARNOLD, AM ;
AYOUB, JI ;
WILSON, KS ;
LATREILLE, J ;
WIERZBICKI, RF ;
HILL, DP .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (04) :633-641